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ABSTRACT 
Kidney stones are one of the oldest known and common diseases in the urinary tract system. Kidney stones are a growing global problem. It is 
also known as Urolithiasis. Lithiasis is a condition where urinary calculus is formed in the kidney and urinary tract.  It is a complicated urinary 
disorder that has gravely troubled the health and quality of human life. It has been associated with an increased risk of end-stage renal failure. 
Urinary stones affect 10-12% of the population in industrialized countries. There are only a few geographical areas in which the stone disease is 
rare, e.g., Germany and in the coastal areas of Japan. The etiology of kidney stone is multifactorial. The most common type of kidney sto ne is 
calcium oxalate formed at Randall’s plaque on the renal papillary surfaces. The mechanism of stone formation is a complex process which 
results from several physicochemical events including supersaturation, nucleation, growth, aggregation and retention of urinary stone 
constituents within tubular cells. These steps are modulated by an imbalance between factors that promote or inhibit urinary crystallization. 
Currently, there is no satisfactory drug to cure and/or prevent kidney stone recurrences.  Conventional agents are being used to control kidney 
stone along with lifestyle management.  Medicinal plants are found to be useful in this metabolic disorder from ancient days due to its no or 
low-toxic nature, easily available in rural areas, cheap; there are fewer chances of recurrence. Thus, further understanding of the 
pathophysiology of kidney stone formation is a research area to manage urolithiasis using new drugs. Therefore, this review has intended to 
provide compiled up-to-date information on kidney stone etiology, pathogenesis and prevention approaches and critically review the available 
literature on various medicinal plants with their antilithiatic activity and screening method of this activity to develop an effective drug to treat 
the disease. 
Keywords: Kidney stones, Urolithiasis, Etiology, Calcium oxalate, Pathophysiology, Medicinal plants  
 
Article Info: Received 10 July 2019;     Review Completed 13 Aug 2019;     Accepted 23 Aug 2019;     Available online 30 Aug 2019 
Cite this article as: 
Chandel VK, Jain S, Choubey A, An Overview on Phyto-molecules and Screening Method of Antiurolithiatic Activity, Journal 
of Drug Delivery and Therapeutics. 2019; 9(4-A):848-857    http://dx.doi.org/10.22270/jddt.v9i4-A.3709                                                                                   
*Address for Correspondence:  
Vinod Kumar Chandel, Madhyanchal Professional University, Bhadbhada Road, Ratibad, Bhopal, MP, 462044 
 
 
Introduction 
Several therapeutic methods are available in the modern 
health care system to treat infectious and non-infectious 
diseases. However, some of these therapies have their own 
limitations, and also are not available to the majority of the 
world’s population due to their accessibility and affordability 
reasons. Because of this, approximately 75% of people, 
mainly from lower economy countries are still dependent on 
herbal remedies for their basic healthcare requirements1. In 
this regard, substantiation of traditional medicines for the 
least life threatening diseases, such as urinary stone and 
hemorrhoids should be considered. Urinary stones (calculi) 
are the solid crystalline masses that can occur anywhere in 
the renal tract and the process of formation of urinary stone 
or appearance of stone anywhere in the urinary tract is 
termed as urolithiasis2. The history of urolithiasis dates back 
to the early age of civilization. Paleopathological evidences 
corroborate its incidence around 7000 years ago3. 
Nephrolithiasis is the condition in which the stone is located 
in the kidney. The term ureterolithiasis refers to the stones 
that are in the ureter; and cystolithiasis (or vesical calculi) is 
used to mention stones which form or have passed into the 
urinary bladder4. The formation of stones in the kidneys, is 
one of the oldest known and widespread diseases in the 
urinary tract system with a relapse rate of 50% in 5-10 
years5,6. It is the third most common disorder among urinary 
diseases7. It has been reported that 10-12% of people in 
industrialized countries (10% of men and 3% of women) 
have a urinary stone during their lives. The rate of 
occurrence is three times more in men than women, due to 
enhancing capacity of testosterone and inhibiting capacity of 
oestrogen hormone in stone formation8. There are only a few 
geographical areas in which stone disease is rare, e.g., in 
Greenland and in the coastal areas of Japan9. The etiology of 
this disorder is multifactorial and is related to genetics, diet 
and low activity10, 11. Calcium-containing stones are the most 
common kidney stones (75-90%), followed by magnesium 
ammonium phosphate (struvite) (10-15%), uric acid (3-
10%) and cystine (0.5-1%) 12. The mechanisms related to the 
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development of kidney stones are not completely 
understood. Generally, it is believed that urolithiasis, the 
process of stone formation in the urinary tract, causes crystal 
aggregation, nucleation and growth of insoluble particles13. 
The stones may cause various symptoms, including pain, 
obstruction, infection and hemorrhage, through the passage 
of stones in the urinary tract system14. Promoters of stone 
formation are calcium, sodium, oxalate, urates, cystine, low 
urine pH, Tamm-Horsfall protein and inhibitors of stone 
formation are divided in two parts, inorganic (magnesium, 
pyrophosphate and citrate) and organic (nephrocalcin 
Tamm-Horsfall protein, protease inhibitors, 
glycosaminoglycans and high urine flow) 15. Some medical 
conditions that increase the risk of development of 
nephrolithiasis include gout, hypertension, diabetes, obesity 
and primary hyperparathyroidism. Management of stone 
disease depends on the size and location of the stones. 
Stones larger than 5mm or stones that fail to pass through 
should be treated by some interventional procedures such as 
extracorporeal shock wave lithotripsy (ESWL), ureteroscopy 
(URS), or percutaneous nephrolithotomy (PNL) 16 and 
transureteral lithotripsy17, 18. These surgeries are complex 
and expensive and do not affect the recurrence of stones17. 
Various medicines, including thiazide as diuretic and alkali-
citrate, are applied to prevent the frequency of 
hypercalciuria and hyperoxaluria which cause calculi 
formation but they are not promising enough due to their 
limited effectiveness and low tolerability18-21. Because of the 
disadvantages of surgical techniques and limited choice in 
pharmacotherapy, exploring new pharmacological therapies 
for the management of kidney stones is worthwhile. Various 
medicinal plants with diuretic, antispasmodic and 
antioxidant activities exert inhibitory effects on 
crystallization, nucleation and aggregation of crystals, 
making them useful for treatment of urolithiasis. In India, in 
the Ayurvedic system of medicine, Varuna, Pashanabheda, 
Gokhru Kulatha were found to be effective in preventing the 
deposition of the stones in experimental rates. 
Pharmacotherapy can reduce the recurrence rate. The use of 
plant is very important as to reduce the side effects related to 
allopathic medicines and treatments. The purpose of this 
paper is to critically review about kidney stones and the role 
of herbal medicines in the management of urolithiasis and 
could serve as a source of information on the present trends 
in research on plants having antiurolithiatic activity. 
Literature search methodology 
Electronic databases, including PubMed, Science Direct, and 
Scopus, were searched for herbal plants and their bioactive 
compounds used for prevention and management of 
urolithiasis from 2005 to act. 2019. The keywords were 
“kidney stone” or “urolithiasis”, or “nephrolithiasis”, or 
“renal calculi”, or “renal stone”, or “antilithiatic”; and “herbal 
plant”, or “herbal herb”, or “phytochemical”. The retrieved 
articles were subclassified into in vitro, in vivo, and clinical 
studies. The studies included were evaluated with respect to 
the potential of the plant to be used as a herbal agent, the 
phytochemical composition of the plant, the kind of kidney 
stone that the herbal agent is effective on, as well as 
underlying mechanisms of action. 
Epidemiology of kidney stones  
Urolithiasis occurs in one out of 20 people at some time in 
their lives. Calcium stones are mostly found in the patients 
and the average age of onset is third to fourth decade (30-
40years). 5% of populations are affected from kidney stone 
with a lifetime risk of passing a kidney stone about 8-10%. 
Looking at the current scenario, our understanding about the 
disease has improved. Today we have statistics which says; 
around 12% population worldwide is suffering from kidney 
stone disease. It affects all ages, sexes and races7,22 but 
occurs more frequently in men than in women. However, 
lifetime recurrence rate is higher in males, although the 
incidence of nephrolithiasis is growing among females23. If 
patients do not apply metaphylaxis, the relapsing rate of 
secondary stone formations is estimated to be 10-23% per 
year, 50% in 5-10 years, and 75% in 20 years of the patient7. 
Global scenario says that this disease is more common in 
western hemisphere (5-9% in Europe, 13-15% in USA, 12% 
in Canada) than eastern hemisphere (1-5%). In the Asian 
countries Saudi Arabia is leading the disease with 20% 
occurrence rate. Overall Asia shows (4-20%) of kidney 
stones which include countries like India, China, Pakistan, 
Myanmar, Thailand, Indonesia, Philippines and UAE24, 25. 
Considering Indian scenario 13-14% of the population has 
the kidney stones24. There are two ‘stone belts’ more prone 
to kidney stones, one belt stretched from Amritsar to Uttar 
Pradesh via Delhi and Agra. Other belt starts from Gujrat to 
Jabalpur in central India26. In south India, Kerala is leading 
with kidney stone disease with prevalence rate of 2643 per 
100,000 adult. Reason for this significant increase in number 
in Kerala among other states in South India, is life style 
diseases like obesity and diabetes are more common and 
steadily increasing with risk 43% in Kerala. There is positive 
relation between diabetes and kidney stone27. 12% of the 
population is estimated to have urinary stones, out of which 
50% may end up with loss of kidneys or renal damage. 
Repeated stone formation is a frequent problem with all 
types of stones and consequently an important part of the 
medical care of patients with stone disease28. 
Etiology 
Reasons of development of kidney stone in some people are 
not totally understood. Beside from the risk factors (intrinsic 
(such as age, sex and heredity) and extrinsic factors such as 
geography, climate, dietary, mineral composition and water 
intake), metabolic condition e.g. cystinuria, hyperuricosuria, 
xanthinuria, hyperoxaluria, hyperthyroidism and distal 
tubular acidosis are some common cause of stone 
formation29. A person with a family history of kidney stones 
may be more likely to develop stones. Urinary tract 
infections, kidney disorders such as cystic kidney diseases, 
and metabolic disorders such as hyperparathyroidism are 
also linked to stone formation. In addition, more than 70% of 
people with a rare hereditary disease called “renal tubular 
acidosis” develop kidney stones. Cystinuria and 
hyperoxaluria are two other rare, inherited metabolic 
disorders that often cause kidney stones. In cystinuria there 
is too much of the amino acid cysteine, which does not 
dissolve in urine and it is voided. This can lead to the 
formation of stones made of cysteine. In patients with 
hyperoxaluria, the body produces too much of the salt 
oxalate. When there is more oxalate that can be dissolved in 
the urine, the crystals settle out and form stones. 
Hypercalciuria is inherited. It is the cause of stones in more 
than half of patients. Calcium is absorbed from food in excess 
and is lost into the urine. This high level of calcium in the 
urine causes crystals of calcium oxalate (CaOx) or calcium 
phosphate (CaPh) to form in kidneys or in the urinary tract. 
Other causes of kidney stones are hyperuricosuria (a 
disorder of uric acid metabolism), gout, excess intake of 
vitamin D, and blockage of the urinary tract. Certain diuretics 
(water pills) or calcium-based antacids may increase the risk 
of forming kidney stones by increasing the amount of 
calcium in the urine.  CaOx stones may also form in people 
who have a chronic inflammation of the bowel or who have 
had an intestinal bypass operation, or ostomy surgery. As 
mentioned above, struvite stones can form in people who 
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have had a urinary tract infection. People who take the 
protease inhibitor indinavir, a drug used to treat HIV 
infection and AIDS, are at risk of developing kidney stones30, 
31. Stones are also classified based on how they are formed in 
the body e.g by infection, non-infection, genetic or drug 
related effect32. 
Non-infection stones: Calcium oxalate, Calcium phosphate 
(including brushite and carbonate apatite), Uric acid. 
Infection stones: Magnesium ammonium phosphate, 
Carbonate apatite, Ammonium urate 
Genetic causes: Cystine, Xanthine, 2,8-dihydroxyadenine 
Drug stones:  
Pathophysiology of urolithiasis diseases  
There are basic two aspects in the pathogenesis of kidney 
stone like as  
(a) Increased urinary flow of stone forming constituent 
elements like calcium, phosphorus, uric acid, oxalate and 
cysteine.  
(b) Physico-chemical change that influence stone formation 
like pH of urine, stone matrix and protective substance in 
urine.  
For a stone to form within the urinary tract, Urine must be 
supersaturated for precipitating crystalline component. The 
agents who can modify nucleation, crystallization, and 
aggregation, pH of the urine also play important role in stone 
formation33.  
Mechanism of urolithiasis: crystallization and retention 
of stones 
The diseased state of urolithiasis becomes apparent only 
when small stone particles are retained within the urinary 
system and grow into clinically relevant stones34.  
Supersaturation of urine, crystallization and retention of 
stone within urinary system are the prominent steps 
involves in the formation of urinary stones.  
Crystallization 
Crystallization represents the first phase of urinary stone 
formation and further includes three steps: crystal 
nucleation, growth and aggregation. 
Nucleation 
The nucleation is a process of formation of a solid crystal in 
solution35. Generation of a crystal can occur by homogeneous 
nucleation when local supersaturation allows spontaneous 
organization of the atoms into the appropriate lattice. 
However, heterogeneous nucleation is more likely to occur 
within complex mixtures in which peculiar proteins provide 
patterns on their surface to organic molecules for the 
formation of the initial crystal lattice36. The organic matrix of 
the stone compositions constitutes around 2.5% of total 
weight, which mainly include small proteins such as albumin, 
Tamm-Horsfall protein and bikunin37. Generally, the kidney 
walls are protected by an anti-adherent glycosaminoglycans 
layer and because of this, nucleation of stone can only occur 
at damaged areas or perhaps just at reduced protective layer 
sites. Nucleation may occur in renal tubules, on bladder 
walls, on normal or damaged cells, on areas denuded of cells 
by certain forms of injury, or at interstitial sites38-40. 
Crystal growth 
After nucleation, crystal growth is the next major step of 
stone formation. In this process, several atoms or molecules 
in supersaturated liquid starts to form clusters. Crystal 
growth is determined by the molecular size and shape of the 
molecule, the physical properties of the material, 
supersaturation levels, pH and defects that may form in the 
crystal’s structure35. 
Aggregation 
Aggregation an important step of stone development and is 
commonly defined as a process in which crystals 
agglomerate and form larger multicomponent particles in 
free solution40. Aggregation of particles in solution is 
determined by a balance of forces, including both 
aggregating and disaggregating effects. Small interparticle 
distances increase attractive forces and favour particle 
aggregation35. The process of crystallization is influenced by 
several promoters and inhibitors, as well as some 
morphoanatomic, dietary and environmental factors. Trace 
elements in the urine, such as fluoride, iron, iodine, 
manganese, molybdenum, nickel, selenium, silicone, 
germanium, vanadium, copper, zinc, chromium, and lithium 
are found to initiate the process of crystallization41. These 
elements act as a nucleus for the formation of the stone, or 
influence the external morphology of growing crystals. They 
may also increase or decrease the speed of the crystallization 
process41, 42 . 
Stone retention 
After the crystallization process is complete, the retention of 
urinary stones within the urinary system is an important 
step in the development of the disease. Urothelium is 
generally thought to be resistant to crystal adherence. 
However, chemical or mechanical urothelial damage may 
promote crystal binding and aggregation43. So far, two 
hypotheses have been put forwarded for retention of urinary 
stones: free particle and fixed particle hypothesis. According 
to the free particle hypothesis¸ the process of nucleation 
occurs entirely in the tubular lumen. As crystals move 
through the renal tubules, rapidly aggregate and grow large 
enough to get stuck within the tubular lumen43. Whereas, in 
fixed particle hypothesis it has been proposed that crystals 
gets adhered to a fixed point, such as renal epithelial cells or 
Randall’s plaque44. Four different possible modes of stone 
retention have been identified in the fixed particle 
hypothesis, namely: 1) growth over white (Randall’s) 
interstitial hydroxyapatite plaque; 2) growth over Bellini 
duct plugs; 3) formation of microliths within inner medullary 
collecting ducts and 4) formation in free solution within the 
calyces or renal collecting system45. 
Kidney stone compositions 
The chemical compositions of urinary stones include crystals 
and noncrystalline phases or the organic material (the 
matrix). The organic matrix of urinary stones consists of 
macromolecules such as glycosaminoglycans (GAG’s), lipids, 
carbohydrates and proteins. These molecules play a 
significant role by promoting or inhibiting the processes of 
kidney stone development. The main components of the 
stone matrix are proteins (64%), nonamino sugars (9.6%), 
hexosamine as glucosamine (5%), water (10%) and 
inorganic ash (10.4%). The matrix acts as a template 
participating in the assembly of kidney stones.The matrix of 
all stones contains phospholipids (8.6%) of the total lipid, 
which in turn represents about 10.3% of stone matrix. Cell 
membrane phospholipids, as part of organic matrix, promote 
the formation of calcium oxalate and calcium phosphate 
stones46. Albumin is the major component of the matrix of all 
stone types47. Brushite stone is a hard phosphate mineral 
with an increasing incidence rate and a quarter of calcium 
phosphate (CaP) patients form stones containing brushite48. 
In the urinary tract, CaP may be present in the form of 
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hydroxy-apatite, carbonate apatite, or brushite (calcium 
monohydrogen phosphate dihydrate, CaHPO4·2H2O). 
Brushite is resistant to shock wave and ultrasonic lithotripsy 
treatment49. 
 Diagnosis and modern therapeutic strategies for 
management and cure of urinary stones 
After physical examination and considering anticipated 
symptoms of urinary stone disease, the diagnosis of urinary 
stone starts with the medical history of the patients; dietary 
data, complete blood cell count, routine urine analysis and 
serum creatinine measurement50. The further diagnosis 
mainly includes ultrasound and imaging tests such as an X-
ray or computerized tomography (CT) scan. Some of the 
stone may not be visualized in X-ray, therefore, in this case, 
ultrasonography is preferred as it detects all types of kidney 
stones51. In many cases, urinary stones can pass 
spontaneously. Because of this, physicians are usually trying 
to manage symptoms of stone disease at an initial stage, 
which includes pain management with analgesia. However, 
the rate of stone passage is highly variable and depends on 
its size and location. If stone fails to pass spontaneously, then 
medical expulsive therapy is generally preferred. This 
treatment regimen can include prescription of 
anti‐inflammatory drugs, antibiotics, calcium antagonists and 
α‐blockers52. However, surgical intervention becomes crucial 
when conservative therapy fails due to complex composition 
and larger size of stones, and/or the patient cannot bear the 
degree of pain until the stone passes53. Surgical treatments 
primarily comprise extracorporeal shock wave lithotripsy 
(ESWL), ureteroscopy (URS), percutaneous pithotripsy 
(PCNL) and open surgery54. Despite several advantages, 
these surgical techniques have some limitations, because 
stone clearance after surgery is dependent on several factors 
such as patient age, stone size, location and number, 
radiological renal features and congenital renal anomalies55. 
The recurrence of stones is another major risk factor for 
surgical and medicament treatments56. It has been found that 
ESWL may cause acute renal injury due to the traumatic 
effect of shockwave and the possibility of infection after 
treatment57.  
Screening method of urolithiasis activity 
Rat model 
Rats represent a well-established, relatively economical 
model that scientists have utilized since the 19th century. 
For urinary stone disease, studies utilizing the rat have 
predominantly focused on reproducing both hypercalciuria 
and hyperoxaluria, two of the most common 
pathophysiologic changes associated with urinary stone 
disease. 
In Vivo animal model 
Sodium oxalate (NaOx) induced model 
As Khan et al. illustrated, different areas of the nephron 
reflect predictable calcium oxalate crystal formation 
depending on time elapsed after intraperitoneal injection of 
sodium oxalate58. Varying doses (3, 5, 7, 9, and 10 mg/kg) of 
sodium oxalate administered to Male Sprague-Dawley rats 
produced persistent hyperoxaluria and crystals in a dose-
dependent fashion59-61. Compared to controls, rats receiving 
10 mg/kg had over 500% more oxalate excreted with 
persistent crystals that remained present up to 7 days after 
injection. Calcium oxalate crystals were appreciated within 
15 min of injection and by 6 h there was noticeable crystal 
aggregation in the ducts of Bellini62. 
 
Glycolic acid induced model 
Using powdered 3% glycolic acid dissolved in drinking 
water, Ogawa et al. demonstrated that male Wistar-strain 
rats produce high levels of 24-h urinary oxalate and 
subsequent calcium oxalate calculi63. Interestingly, this study 
also showed that adding magnesium (Mg) salts to a high 
glycolic acid diet increased urinary citrate levels despite 
relatively high levels of urinary oxalate excretion. 
Ethylene glycol induced model 
Administration of EG in drinkingwater has been shown to 
result in consistent induction of hyperoxaluria, crystalluria 
and calcium oxalate nephrolithiasis64. Delivering solely 
0.75% EG to male rats eventually yielded persistent 
crystalluria at 12 days and renal crystal deposits at 3 
weeks65. To enhance the development of crystal deposition, 
EG often has been combined with other agents such as 
ammonium chloride (AC) to reduce urinary pH, as well as a 
vitamin D or calcium chloride to result in subsequent 
hypercalcemia and hypercalciuria 59,65,66. This lithogenic 
combination decreased the time for crystalluria from 12 to 3 
days, and detectable calcium oxalate nephrolithiasis from 3 
weeks down to 1 week59. However, multiple studies have 
shown EG to be a toxic agent that can cause multi-organ 
failure57. Yamaguchi et al. demonstrated that the 
combination of EG and AC is detrimental to rat health e with 
rats having lower weights, worsening renal function, and 
increased urinary N-acetyl-b-D-glucosaminidase (NAG), an 
indicator of renal toxicity68. Other studies have also found 
that lipid peroxidation, increased free radicals, and metabolic 
acidosis also take place as a result of EG Refs69. 
Hydroxy-L-proline induced model 
Hydroxy-L-proline (HLP) is derived from the amino acid 
proline and is a component of collagen that is metabolized to 
both pyruvate and glyoxalate, primarily in the renal proximal 
tubule and hepatocyte mitochondria70. It is a common 
ingredient in Western diets and has been shown to be less 
toxic than other lithogenic agents. Intraperitoneal injection 
of HLP has resulted in the presence of calcium oxalate 
crystals within the rat kidney71. A large dose of 
4-HLP (2.5 g/kg) induced both calcium oxalate dihydrate 
(Weddellite) and calcium oxalate monohydrate (Whewellite) 
crystals, detected by scanning electron microscopy. Khan et 
al. provided 5% HLP (weight/weight HLP/chow) to male 
Sprague-Dawley rats and compared treated vs controls at 4, 
6, and 9 weeks72. At 4 weeks, all treated rats were found to 
have CaOx crystals throughout the regions of the kidney, 
with the majority present in the tubular lumens of the distal 
tubules and collecting ducts. By 9 weeks these crystals were 
mainly located at the tips of the renal papillae. Bushinsky et 
al. found that the addition of 1%, 3%, and 5% trans-4- HLP to 
GHS rats altered urine calcium and stone type, with rats 
receiving 5% HLP having lower urine calcium excretion and 
consistent calcium oxalate calculi composition73. 
Zinc disc induced model 
Rats were anesthetized with sodium pentobarbitone (40 
mg/kg, ip). A suprabic incision was made and the urinary 
bladder was exposed. A small cut was made at the top of the 
bladder. The urine was then aspirated aseptically into a 
sterile vial for bacteriological examination and pH 
determination (using narrow range pH paper BDH). 
Previously weighted sterile zinc discs were inserted into 
bladder, and the incision was closed with a single suture 
using absorbable 4-0 chronic catgut (Ethicon) and the rats 
were allowed to recover for one week. The implantation of 
zinc foreign bodies into the urinary bladder induce growth of 
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urinary stones and hypertrophy of the organ smooth 
musculature that were greater in males than in female from 
4 & 8 w surgery, respectively74-76. 
Dietary manipulation 
Aiming for an alternative crystal induction method compared 
to HLP, Wiessner et al. found that a 5% level of potassium 
oxalate was required to produce calcium oxalate crystals in 
both Dahl saltsensitive and Brown Norway male rats77. 
Meanwhile hyperoxaluric rats deprived of dietary Mg 
demonstrated increased production of calcium phosphate 
(apatite) stones78. Intentional vitamin B6 deficiency can also 
be employed in rats to enhance hyperoxaluria, 
hypocitraturia and subsequent calcium oxalate crystal 
formation79. Studies exposing these pyridoxine deficient rats 
to supplemental Mg demonstrated their ability to counteract 
the hypocitraturia and effectively prevent calcium oxalate 
crystal formation80. 
Xenoplantation Model 
 Stone particles were extracted by PCNL (percutaneous 
lithotomy) from one male patient with renal stones. The 
selected stone is cut with a blunt instrument into sections 
with a diameter of 2-3 mm, weighed and maintained in a 
sterile environment, before use. Eight-week old male rats 
weighing about 250-300 gm were selected and randomized 
into three groups: control, standard and test groups. The rats 
were anesthetics by intraperitoneal injection of sodium 
pentobarbital (50 mg/kg body weight), and a suprapubic 
incision exposed the bladder. Following this, a 4-5 mm 
incision was made at the top of the bladder, and one 
prepared stone particle was inserted in each rat, and then 
the bladder and the suprapubic incision was closed 
respectively. Ethylene glycol was supplied in drinking water 
at a final concentration of 1% from the second day (day 1) 
postoperatively for four weeks. After four weeks, kidney and 
urinary bladder were dissected, and the kidneys were 
dehydrated in a graded ethanol series and embedded in 
paraffin. The renal stone formation was assessed by von 
Kossa histochemical staining. Bladder stone was harvested, 
weighed and maintained in 75% ethanol for 24 h, before the 
stone being embedded in auto-polymerizing resin and 
sectioned transversely with the diamond wire saw to select 
the best section pane. Sectioned blocks were then fixed on a 
glass slide with thermoplastic glue and polished successively 
using a 1, 200 grit sandpaper and a mix of alumina polishing 
compounds (3, 1 and 0.3 μm) with a small volume of water 
until it was possible to observe the core clearly under a 
transmitted light microscope81. 
Chemically induced lithiasis in weanling rats 
 Calculi is induced in the urinary tract of weanling Fischer-
344 rats (postnatal day 28) in less than two weeks by 
exposure to terephthalic acid (TPA) at 3-5% in the diet or 
dimethyl terephthalate (DMT) at 1-3% of diet. Specified rats 
of 24 which randomly divided into four groups each group 
containing six rats. Group-I, II, III, and IV acts as control 
received vehicle, disease control (positive control) received 
(TPA)/(DMT) for two weeks, standard received (TPA/DMT) 
and cystone 750 mg/kg body weight p.o and the last group, 
i.e. IV serves as a test received (TPA/DMT) plus test drug. 
After the treatment period, various biological samples are 
collected and the parameters are measured and compared82. 
Mild tubular damage for hyperoxaluric rats induces renal 
lithogenesis 
 It is a two-step or two hit model of lithogenesis used to 
assess the antilithiatic activity of test drugs. In the first step, 
it is used to induce crystalluria (hyperoxaluria) which is a 
necessary step but not sufficient to induce lithiasis. In the 
second step, it causes tubular damage that induces lithiasis83. 
In vitro models 
Determination of effect on CaC2O4 crystallization  
The CaC2O4 Crystallization was determined by the time 
course measurement of turbidity change due to the crystal 
formation and aggregation in the metastable situations of 
Ca2+ and oxalate, stock solutions of CaCl2 (8.5 Mm) and 
Na2C2O4 (1.5 Mm). Containing 200 mM NaCl and 10 mM 
sodium acetate were adjusted to pH 5.7. An aggregometer 
devised for platelet aggregation studies based on the 
measurement of optical density at 620 nm was used to 
investigate the event of CaC2O4 crystallization. The CaCl2 
solution (0.5 ml) was stirred constantly both in the absence 
and presence of different concentrations of the test material 
or reference drug: potassium citrate at 37 0C. After obtaining 
a stable base line, crystallization was induced by the addition 
of Na2C2O4 solution (0.5) to obtain the final concentration of 
Ca2+ as 4.25 and oxalate as 0.75 Mm. The time course 
measurement of turbidity was simultaneously started on a 
chart, moving at the speed of 30 mm/h and continued for 15 
min with constant stirring of the solutions. All experiments 
were run in triplicate, Slope of nucleation (SN) and 
aggregation (SA) phases were calculated using linear 
regression analysis. Using the slopes, the percentage 
inhibition was calculated as [(1-Sm/Sc) X 100], where Sm is 
slope in the presence of modified and Sc is slope of the 
control experiment. To determine the effect of incubation 
with the test material on CaC2O4 crystal formation, stock 
solutions of CaCl2 and Na2C2O4 having composition similar to 
those in the kinetic study were used. CaCl2 solutions, 
containing different concentrations of the test material or 
potassium citrate, were aliquoted (0.5) to the flat bottomed 
tubes in a 24 well plate. To each of these tubes Na2C2O4 
solution (0.5) was added to obtain the final concentration of 
Ca2+ as 4.25 and oxalate as 0.75 mM. Each concentration of 
the test material was prepared in triplicate. The plates were 
then incubated in a shaking water bath at 90 
oscillations/min at a temperature of 370C for 45min. Each 
tube then observed under an inverted microscope for crystal 
morphology and count in five randomly selected fields 
(200x) 84.  
Nucleation assay  
The method used similar to that descried85. The solutions of 
calcium chloride and sodium oxalate were prepared at the 
final concentration of 3mmol/l and 0.5 mol/l, respectively, in 
a buffer containing Tris 0.05 mol/l and Nacl 0.15 mol/l at pH 
6.5. Both solutions were filtered through a 0.22μm filter; 33 
ml of calcium chloride solution was mixed with 3.3 ml of the 
test at different concentration. Crystallization was started by 
adding 33 ml of sodium oxalate solution. The final solution 
was magnetically stirred at 800 rpm using a PTFE-coated 
stirring bar. The temperature was maintained at 37 °C. The 
absorbance of the solution was monitored at 620 nm after 
every 1 min. The percentage inhibition produced by test was 
calculated as [1-(Tsi/TSC)]x100, Where Tsc was the turbidity 
slope in the presence of the inhibitor86.  
Growth assay  
Inhibitory activity against CaOx crystal growth was 
measured using the seeded, solution-depletion assay an 
TEST solution of 10 mM Tris-HCl containing 90 mM NaCl was 
adjusted to pH 7.2 with 4 N HCl. Stone slurry (1.5 mg/ml) 
was prepared in 50 mM sodium acetate buffer (pH 5.7) CaOx 
monohydrate crystal seed was added to a solution containing 
1 mM CaCl2 and 1 mM sodium oxalate (Na2C2O4. The reaction 
of CaCl2 and Na2C2O4 with crystal seed led to deposition of 
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CaOx (CaC2O4) on the crystal surfaces, thereby decreasing 
free oxalate that is detectable by Spectrophotometer at λ214 
nm. When test is added into this solution, Depletion of free 
oxalate ions will decrease if the test sample inhibits CaOx 
crystal growth. Rate of reduction of free oxalate was 
calculated using the baseline value and the value after 30- 
second incubation with or without test sample. The relative 
inhibitory activity was calculated as follows: % Relative 
inhibitory activity =[(C-S)/C]x100, where C is the rate of 
reduction of free oxalate without any test sample and S is the 
rate of reduction of free oxalate with a test sample86, 87.  
Calcium phosphate assay  
Calcium phosphate (CaP) assay was studied on in vitro 
homogeneous systems of initial mineral phase formation for 
CaP, its subsequent growth and demineralization by 
employing 5.0 ml systems which was prepared by adding 0.5 
ml of KH2 PO4 (50 mM), 0.5 of CaCl2 (50 mM), 2.5 ml of Tris 
buffer (210 mM NaCl + 0.1 mM tris HCl) and increasing 
volume of test ranging from 0.2 ml to 1.5 ml by subsequently 
decreasing the volume of water ranging from 1.5 ml to 0.0 
ml. This system was centrifuged at 4500 rpm and 
precipitates so obtained were dissolved in 5 ml of 0.1 N HCl. 
This 5 ml system for mineralization88,89. For the growth, 
firstly 5 ml systems were prepared using standard protocols 
then again 5 ml were re-grown on the same tubes with the 
additions of increasing volumes of the test. Calcium and 
phosphate were then estimated on the precipitates obtained 
and dissolved in 0.1 N HCl. In case of control no test was 
added. T checks the demineralization, again 5 ml system was 
prepared having no test added to that and precipitates were 
obtained. To these precipitates, 2.5 ml of Tris buffer (210 
mM NaCl+0.1 mM Tris HCl) and increased volumes of test 
ranging from 0.2 ml to 1.5 ml with subsequently reduced 
volume of water was added and then centrifuged at 4500 
rpm for 15 min. Calcium and phosphate were then estimated 
in supernatant obtained after centrifuged. The Ca2+ and 
HPO4-˙ ions were estimated by the methods90,91 respectively. 
Percentage inhibition of mineral phase in the presence of test 
was calculated as % inhibition= ((C-T)/C)x100, where T is 
the concentration of Ca2+ or HPO42˙ ion of the precipitates 
formed in test having test ranging from 0.2 ml to 1.5 ml in 
the assay systems and C is the concentration of Ca2+ or 
HPO42˙ ion of the precipitate formed in control systems 
which had distilled water (Millipore) and no test92.  
Calcium oxalate crystal assay 
Inhibitory activity of test was also checked on calcium 
oxalate crystal growth. A 4 ml system was prepared to check 
the effect of the test in inhibiting growth of calcium oxalate 
crystals. In this systems, 1 ml each of 4 mM calcium chloride 
and 4 mM sodium oxalate were added to a 1.5 ml solution, 
containing NaCl (90 Mm) buffered with Tris HCl (10 mM) pH 
7.2. To this 30 μl of calcium oxalate monohydrate (COM) 
crystal slurry (1.5 mg/ml acetate buffer) was added 
consumption of oxalate begins immediately after COM slurry 
addition and was monitored for 600 sec by disappearance of 
absorbance at 214 nm. When test is added into this solution, 
depletion of free oxalate ions will decrease if test inhibits 
calcium oxalate crystal growth. Rate of reduction of free 
oxalate was calculated using the baseline value and the value 
after 30 sec incubation with or without the test. The relative 
inhibitory activity was calculated =((C-S)/C)x100, where C is 
the rate of reduction of free oxalate without any test sample 
and S is the rate of reduction of free oxalate with a test 
sample92. 
Lactate dehydrogenase leakage assay  
LDH leakage assay was performed by the methods 
described93. The 6.6 mM NADH and 30 mM sodium pyruvate 
were prepared in Tris (0.2M, pH 7.3) reaction was initiated 
with the addition of 50 μl of the test sample and the 
disappearance of NADH was monitored at 340 nm, for 5 min 
at an interval of 1 min. The percentage of LDH release was 
calculated by dividing the activity of LDH in the supernatant 
by the LDH activity measured after complete cell lysis 
achieved by sonication86. 
Herbal drugs used in treatment of urolithiasis 
Herbal medicines have lesser side effects than the modern 
medicines and reduce the recurrence rate of renal stone94. 
The complete mechanism of action of plant based remedies 
is lacking but plant based phytotherapeutic agents are more 
efficacious in urolithiasis treatment. Allopathic medicines 
target only one aspect of urolothiatic pathophysiology while 
plant based therapy is known to be effective against different 
stages of stone pathophysiology. Medicinal plant extracts 
show antiurolithiatic property exert by altering the ionic 
composition of urine, decreasing the calcium ion 
concentration or increasing magnesium and citrate 
excretion. Herbal medicines have several phytoconstituents 
and exert their beneficial effects in urolithiasis by multiple 
action like diuretic or lithotriptic properties. Diuretic action 
is also needed to increase the amount of fluid going through 
the kidneys and flush the deposits95. Drug with multiple 
mechanisms of protective action may be one way forward in 
minimizing tissue injury to human disease96. Most of the 
traditional remedies were taken from plants and their use is 
not well established through systematic pharmacological and 
clinical studies except for some composite herbal drugs and 
plants. These plant products are reported to be effective in 
decreasing the recurrence rate of renal calculi with no side 
effects. Some of the plants which showed promising results 
in in vivo antiurolithiatic models are given in Table 1.
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Table 1. Details regarding part used, plant extracts and study designs which include model used97-126. 
Plant Part Extract Experiment model References 
Adiantum capillus 
veneris 
 
Whole plant 50% ET 0.75% Ethylene glycol and 1% 
Ammonium chloride 
Ahmed et al., 2013 
Bergenia ligulata Rhizome 70% E 0.75% Ethylene glycol and 1% 
Ammonium chloride 
Bashir & Gilani, 2009 
Berberis vulgaris Root Bark B, AQ 0.75% Ethylene glycol and 1% 
Ammonium chloride 
Bashir et al., 2010 
Boerhaavia diffusa Root AQ 0.5 % Ethylene glycol Pareta et al., 2011 
Citrus medica Fruit FJ 0.75% (v/v) Ethylene glycol Shah et al., 2014 
Costus igneus Stem ET 0.75% (v/v) Ethylene glycol Manjula et al., 2012 
Cynodon dactylon Rhizome AQ 0.75% Ethylene glycol and 
Ammonium chloride 
Atmani et al., 2009 
Desmodium styracifolium 
and Pyrrosiae petiolosa 
Whole plant AQ Calculi producing diet (CPD ) Mi et al., 2012 
Flos carthami Whole plant CH 0.75% Ethylene glycol Lin et al., 2012 
Foeniculum vulgare and 
Cymbopogon proximus 
Whole plant FB 70 mg/ kg Sodium oxalate Ibrahim and El-
Khateeb, 2013 
Helichrysum  
plicatum 
Flower 50% ET 1% Ethylene glycol and 1% 
Ammonium chloride 
Bayir et al.,2011 
Helichrysum 
graveolens and 
Helichrysum 
stoechas 
Flower Decoctio
n extract 
70 mg/kg Sodium oxalate Orhan et al., 2015 
Hibiscus sabdariffa  Calyces AQ 0.75% Ethylene glycol and 1% 
Ammonium chloride 
Laikangbam &Devi, 
2011 
Holarrhena 
antidysenterica 
Seed 70% ET 0.75% Ethylene glycol and 1% 
Ammonium chloride 
Khan et al., 2012 
Launaea procumbens Leaf ME 0.75% Ethylene glycol Makasana et al.,2014 
Lemon Juice LJ 0.75% Ethylene glycol and 
2%Ammonium chloride 
Touhami et al.,2007 
Melia azedarach Leaf 70% ET 0.75 % Ethylene glycol Dharmalingam etal., 
2014 
Moringa oleifera Root 
wood 
 
AQ, ET 0.75 % Ethylene glycol Karadi et al.,2006 
Orthosiphon grandiflorus, 
Hibiscus 
sabdariffa and 
Phyllanthus amarus 
Whole 
plant 
 
AQ Feed a diet 
containing 3% glycolic acid to 
produce hyperoxaluria 
and kidney stones. 
Woottisin et al.,2011 
Orthosiphon 
grandiflorum 
Leaf AQ 0.5% Ethylene glycol and 
vitamin D3 in salad oil 
Akanae et al.,2010 
Quercus salicina 
Blume /Quercus 
stenophylla 
Makino 
Leaf AQ 0.5% Ethylene glycol 
 
Moriyama et al.,2009 
Paronychia argentea Aerial 
part 
 
AQ, B IP Sodium oxalate (7 mg/100 g of 
bw) 
Bouanani et al.,2010 
Punica granatum Fruit ME ME, CH 0.75% Ethylene glycol Rathod et al.,2012 
Phyla nodiflora Whole 
plant 
95% ET Gentamycin and Calculi 
producing diet. 
Doddola et al.,2010 
Psidium guajava Leaf 95% ET 0.75% Ethylene glycol Nagar et al.,2015 
Rubia cordifolia 
 
Root 70% ET 0.75% Ethylene glycol and 1% 
Ammonium chloride 
Divakar et al.,2010 
Rosa canina  
 
Fruit 
 
50% ME 
 
1% Ethylene glycol Nasrabadi et al.,2012 
Sesbania grandiflora 
 
Leaf FJ Rat Pellet Feed with 5 % 
Ammonium oxalate 
Doddola et al., 2008 
Solanum 
xanthocarpum 
Fruit 50% ET 0.75% Ethylene glycol Patel et al., 2012 
Trachyspermum ammi Seed IP 0.4 % Ethylene glycol and 1 % 
Ammonium chloride 
Kaur et al ., 2009 
AQ: Aqueous extract, B: Butanol, CH: Chloroform, EA: Ethyl acetate, ET: Ethanol, FB: Formulated beverage, FJ: Fresh juices, HE: 
Hexane, IP: Isolated protein, LJ: Lemon juice, ME: Methanol. 
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Different polyherbal formulations in urolithiasis 
1. Cystone   
2. Rilith  
3. Renomet  
4. Polyherbal I  
5. Polyherbal II  
6. Neeri –KFT  
7. Polyherbal formulation III  
8. Gokshuradi polyherbal Ayurvedic formulation  
9. Crashcal  
10. Lithocare127  
Marketed herbal formulations having 
antiurolithiatic activity 
There are many marketed formulations which are having 
antiurolithiatic activity; some of them are Cystone (Himalaya 
Drug Company, India), Calcuri (Charak Pharmaceuticals, 
Bombay, India) and Chandraprabha bati (Baidyanath, India). 
These formulations have been widely used clinically to 
dissolve urinary calculi in the kidney and urinary bladder. 
Pharmacological and clinical studies carried out on a 
composite herbal formulation, Trinapanchamool consisting 
of five herbal drugs namely Desmostachya bipinnata, 
Saccharum officinarum, Saccharum nunja, Saccharum 
spontaneum and Imperata cylindrica was found to be 
effective both as prophylactic in preventing the formation 
and as curative in dissolving the pre-formed stones in albino 
rats. The antiurolithiatic activity of this formulation has been 
attributed to its diuretic activity128. 
Dietary plants for the prevention of kidney stones 
Green tea (Camellia sinensis), Raspberry (Rubusidaeus, from 
Rosaceae family), Rubia cordifolia (madder or Indian 
madder), Parsley (Petroselinum crispum), Pomegranate 
(Punica granatum), Pistacia lentiscus, Solanum 
xanthocarpum, Urtica dioica or “Stinging Nettle”, Dolichos 
biflorus (horse gram), Ammi visnaga, Nigella sativa, Hibiscus 
sabdariffa, Origanum vulgare129. 
Conclusion  
The present review states the different steps involved in 
kidney stone disease. It explains the mechanism of formation 
of the kidney stones.  As there is no proper medicine in 
Allopathy for the management of anti-lithiasis and also the 
surgical treatment has the more chances of recurrence, these 
two factors particularly diverted the large population 
toward the use of herbal medicines. Medicinal plants have 
wide acceptance due to a large number of advantages such 
as lesser toxic effects safe, effective, cheap (cost effective), 
fewer chances of recurrence of disease, easily available in 
rural areas. The present paper provides information 
regarding the potential medicinal plants used in the 
management of anti-lithiasis and also about the screening 
models of anti-lithiasis in order to develop a new drug for 
the management of anti-lithiasis to overcome the various 
disadvantages faced by the wide range of population and get 
relieved from the disease. Most of these studies were 
preliminary, carried out in animals and are not sufficient for 
the development of a pharmaceutical product. Still, intensive 
preclinical and clinical studies are required to evaluate the 
efficacy and toxicity of these plant products. Further, 
chemical studies of the plants are needed to isolate the 
active principles and investigate them in order to identify a 
promising Lead compound.  Let us hope for the development 
of the safe and effective drug for the management of anti-
lithiasis. 
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